In the absence of data, we cannot draw any conclusion to support or refute the adoption of singing as an intervention for people with bronchiectasis. Given the simplicity of the potentially beneficial intervention, future randomised controlled trials are required to evaluate singing therapy for people with bronchiectasis.
P L A I N L A N G U A G E S U M M A R Y

The effects of singing for children and adults with bronchiectasis
People with bronchiectasis (a chronic lung condition) have chest symptoms that include chronic wet cough, fatigue and shortness of breath. Their lung function can also decline with time. Singing may support lung function and enhance quality of life in people with bronchiectasis. The review found no randomised controlled trials that evaluated the benefits of singing in bronchiectasis. As there is no data, we cannot conclude whether or not singing is a beneficial intervention for people with bronchiectasis.
B A C K G R O U N D Description of the condition
(Please see Appendix 1 for explanations of medical terminology used.) Bronchiectasis, commonly termed an 'orphan disease' (i.e. very rare), is a major cause of respiratory morbidity especially in developing countries (Karadag 2005; Karakoc 2001) and in pockets of affluent countries (Chang 2008) . The underlying causes of bronchiectasis varies from post recurrent respiratory infections to rare immune deficiencies. However, bronchiectasis is also a common pathway for a variety of diseases. Thus, bronchiectasis also occurs in common (e.g. chronic obstructive pulmonary disease (COPD) (O'Brien 2000) and uncommon respiratory diseases (e.g. bronchiolitis obliterans and sarcoidosis) as well as non primary respiratory (e.g. autoimmune) diseases. When bronchiectasis is present with another underlying disorder, it increases the morbidity and mortality of the underlying diseases (Keistinen 1997). For example, in diseases like COPD the presence of bronchiectasis has been reported in 29-50% of cases (O'Brien 2000). When present, bronchiectasis increases the severity and frequency of respiratory exacerbations (Gursel 2006). Thus, management of the symptoms and severity of bronchiectasis has important clinical implications for management of respiratory conditions. Laenec's definition of bronchiectasis (1819) was originally based on post-mortem histopathology. Later, bronchograms which were first described in 1951, became the gold standard for diagnosis. This method has now largely been replaced by high-resolution computerized tomography (HRCT) scans of the chest. Currently, bronchiectasis is defined by 'irreversible dilatation of peripheral airways' and, is usually diagnostically established radiologically by chest HRCT scans. The key features of bronchiectasis in HRCT scans are dilated bronchi in the periphery of the lung and bronchial wall thickening, and lack of tapering. Clinically, particularly in children, this radiological definition is problematic. It is not known at what stage of the disease process HRCT signs of bronchiectasis occur, and CT definitions are derived from adult populations; moreover, chest HRCT scans performed in different states of health may yield different results (Chang 2008b). The dominant symptoms and signs of bronchiectasis are productive (cough with phlegm) or wet sounding cough, dyspnoea on exertion and presence of other respiratory signs (clubbing, chest wall deformity, respiratory noises such as wheezing or crepitations on auscultation) (Chang 2008b). In the long term, pulmonary decline may occur. As for patients with COPD, children and adults with bronchiectasis also suffer from recurrent acute exacerbations, some of whom require hospitalised treatment (Chang 2008). Effective management of bronchiectasis aims to improve quality of life (QoL) and reduce the frequency or severity of respiratory exacerbations and/or long term pulmonary decline (Chang 2008). Several studies have reported that people who employ diaphragmatic breathing and activate respiratory muscles, such as trained singers, exhibit more efficient pulmonary capacity than nontrained singers (Collyer 2008 , Formby 1987 . In people with respiratory disease, anecdotal evidence suggests that adjunctive therapies that include breathing manoeuvres, such as singing, have significant health benefits for respiratory function (Stacy 2002) and psychological well being (Unwin 2002). In a small non-controlled study in adults with emphysema, a singing program improved quality of life and functional outcomes, such as decreased breathlessness, but had no effect on physical health (FEV 1 , distance walked) (Engen 2005).
Description of the intervention
Singing requires well-controlled respiratory manoeuvres due to the greater range of pitch accessed during singing compared with speaking, greater length of musical phrases than spoken language, and the greater dynamic range used in singing songs. To meet these artistic as well as physical challenges, singers employ the diaphragmatic breathing method. The diaphragm as a primary inspiratory muscle generates the necessary subglottic pressure for singing. Louder and higher sounds are associated with higher lung volumes. Respiratory muscles such as the transversus abdominis, external and internal obliques, and the intercostals must also be fully engaged to regulate air flows during singing. Thus, classically trained singers exhibit efficient breath management and greater use of their lung capacity than non-singers (Leanderson 1988, Thomasson 1999 , Collyer 2008 . Respiratory muscles also play an important role in producing an effective cough, which is essential for lung health in patients with bronchiectasis. For an effective cough, high subglottic pressure and strong expiratory force are necessary (Kang 2006). For increasing one's ability to produce maximal expiratory pressure, it is necessary to employ diaphragmatic breathing because it assists with increased lung volumes and strengthened respiratory muscle capacity (Sapienza 2002). Singing can provide not only health benefits but also enjoyment. Studies found that when singing/music was part of a breathing exercise, participants with asthma demonstrated better treatment compliance due to enjoyment, which enhances motivation 
How the intervention might work
Singing as an intervention for respiratory conditions involves, in addition to the vocal folds and laryngeal apparatus, diaphragmatic breathing and activation of the muscles of the entire respiratory system. Diaphragmatic breathing during singing activates respiratory muscles, which support efficient deep inhalation and slow exhalation (Sundberg 1987). This increases respiratory muscle strength, which increases lung volume and assists effective coughing (Kang 2006).
Most songs contain musical phrases of greater length than spoken utterances, notes of various pitch, and changing dynamics (soft/ loud), which actively engage and work the respiratory muscles. A singing intervention can be carried out in a one-to-one or group setting in a non-judgmental and supportive environment. The program needs to be of sufficient length and intensity to allow the participants to master the diaphragmatic breathing technique. This can vary from patient to patient, depending on their age, background, illness severity, past experience with singing and music, and the relationship between the singing facilitator and the patient. A study with emphysema patients ( > 60 age) indicated that at least two half-hour sessions are necessary for learning the diaphragmatic breathing method correctly (Engen 2005).
Why it is important to do this review
Although there is some evidence to suggest that singing, as a relatively low-cost adjunct therapy to more conventional regimes, has the potential of improving health outcomes, no systemic review of singing in bronchiectasis has been carried out.
O B J E C T I V E S
To evaluate the effects of a singing intervention in addition to usual therapy on the quality of life, morbidity, respiratory muscles and pulmonary function of children and adults with bronchiectasis during (a) stable bronchiectasis and (b) an exacerbation of bronchiectasis
M E T H O D S Criteria for considering studies for this review Types of studies
Randomised controlled trials (RCTs)
Types of participants
Children or adults with bronchiectasis (defined clinically or radiologically) not related to cystic fibrosis. Exclusion criteria: Participants with cystic fibrosis or with other diseases where bronchiectasis is not present.
Types of interventions
All types of singing programs that include diaphragmatic breathing, which are carried out in a group (choir) or one-to-one setting with a singing teacher or instructor for a minimum of two half-hour sessions. Studies comparing singing with a sham group that did not involve activation of the respiratory muscles were not considered. Studies using non face-to-face delivery format, such as using DVD or CD, were not considered, as these formats could not address some important issues, such as how to use the voice in a healthy way while singing, and to obtain immediate feedback on singing practice, the posture and the breathing technique. Further individual or group singing sessions can also be adjusted to the levels of singers, which is hard to be achieved through pre-made media, such as DVD or CD. 
Types of outcome measures
Search methods for identification of studies Electronic searches
The following topic search strategies were used to identify the relevant randomised controlled trials listed on the electronic databases: ("bronchiectasis" OR "suppurative lung disease" as (text word) or (MeSH )) AND ("singing" OR "songs" OR "sing" OR "music" Or "diaphragm" OR "breathing exercise" OR "voice" OR "voice training" OR "vocalise" OR "choir" as (text word) or (MeSH )) Trials were identified from the following sources:
1 
Data collection and analysis
Selection of studies
Retrieval of studies: From the title, abstract, or descriptors, two review authors (JI, AC) independently reviewed the literature search results to identify potentially relevant trials for full review. 57 abstracts were identified and four papers were retrieved. The same two authors independently assessed the retrieved articles but no studies met the inclusion criteria. It was planned that any disagreement would have been resolved by third party adjudication (DK). The 2011 update search identified nine references, none of which were eligible for inclusion.
Data extraction and management
Trials that satisfied the inclusion criteria were to be reviewed and the following information recorded: study setting, year of study, source of funding, participants' recruitment details (including number of eligible people), inclusion and exclusion criteria, other symptoms, randomisation and allocation concealment method, numbers of participants randomised, blinding (masking) of participants, care providers and outcome assessors, duration of intervention, previous singing training, co-interventions, numbers of patients not followed up, reasons for withdrawals from study protocol (clinical, side-effects, refusal and other), details on sideeffects of therapy, and whether intention-to-treat analyses were possible. Data were to be extracted on the outcomes described previously and further information was to be requested from the authors where required.
Assessment of risk of bias in included studies
In order to assess the risk of bias, two review authors would have assessed independently the quality of the studies included in the review using the RevMan 'Risk of Bias' table.
Allocation concealment
We would have assessed whether allocation was adequately concealed, in order to prevent both the participants and the investigators from foreseeing the assignment, for example, when using central allocation, opaque sealed envelopes, etc.
Generation of the allocation sequence
Each study would have been graded for the generation of allocation sequence as follows:
1. Low risk bias, if methods of randomisation included using a random number table, computer-generated lists or similar methods;
2. Uncertain risk of bias, if the trial was described as randomised, but no description of the methods used to allocate participants to treatment group was described; 3. High risk of bias, if methods of randomisation included alternation; the use of case record numbers, dates of birth or day of the week, and any procedure that was entirely transparent before allocation.
Blinding (or masking)
Each study would have been graded for blinding as follows:
1. Blinding of outcome assessor to treatment allocation.
Follow up
Each study would have been graded as to whether numbers of and reasons for dropouts and withdrawals in all intervention groups were described; or if it was specified that there were no dropouts or withdrawals.
Dealing with missing data
We contacted the primary investigators to request further information where required.
Assessment of heterogeneity
Any heterogeneity between the study results was to be examined, described and tested to see if it reached statistical significance using the chi-squared test. We consider heterogeneity to be significant when the P value is less than 0.10 (Higgins 2008). We also planned to use the I 2 statistic, where heterogeneity is categorised such that a value of under 25% is considered low, around 50% is considered moderate and over 75% is considered a high degree of heterogeneity (Higgins 2003).
Assessment of reporting biases
If we were able to combine data and if meta-analysis was possible, we would have assessed publication bias using a funnel plot. We would have tried to identify and report on any selective reporting in the included trials.
Data synthesis
It was planned that for the dichotomous outcome variables of each individual study, odds ratio (OR) would have been calculated using a modified intention-to-treat analysis. An initial qualitative comparison of all the individually analysed studies would have been examined as to whether pooling of results (meta-analysis) was reasonable. This would take into account differences in study populations, inclusion/exclusion criteria, interventions and outcome assessment. It was planned that the results from studies that met the inclusion criteria, and reported any of the outcomes of interest, were to be included in the subsequent meta-analyses. The summary weighted odds ratio and 95% confidence interval (CI) (fixed-effect model) would have been calculated (Cochrane statistical package, RevMan version 5). It was planned that numbers needed to treat (NNT) was to be calculated from the pooled OR and its 95% CI applied to a specified baseline risk using an online calculator (Cates 2003). If studies report outcomes using different measurement scales, the standardised mean difference would have been estimated. Any heterogeneity between the study results was to be described and explored. The 95% CI estimated using a random-effects model was to be included whenever there were concerns about statistical heterogeneity.
Subgroup analysis and investigation of heterogeneity
The following a priori subgroup analyses were planned: 1. Children (aged 18 years or less) and adults (>18 years) 2. Participant type (bronchiectasis as primary disease versus bronchiectasis as co-existent disease) 3. Type of singing intervention (e.g. short term: less than one month; medium term:1-6 months; long term > 6 months; type of training) 4. Stable state vs exacerbation phases of bronchiectasis 5. Severity of bronchiectasis (based on FEV1: >80% classified as mild, 50-79% classified as moderate, 30-49% classified as severe, <30% classified as very severe)
Sensitivity analysis
Sensitivity analyses were also planned to assess the impact of the potentially important factors on the overall outcomes:
1. Variation in the inclusion criteria 2. Risk of bias in the included studies, (particularly whether allocation was well concealed) 3. Differences in outcome measures 4. Analysis using random effects model 5. Analysis by "treatment received" or "intention-to-treat"
R E S U L T S Description of studies
We found four potential studies but none fulfilled inclusion criteria. Please see Characteristics of excluded study below.
Results of the search
The search identified 64 abstracts in total. We did not identify any suitable trials for inclusion.
Excluded studies
One study (Manternach 2008) 
Risk of bias in included studies
No study was included.
Effects of interventions
In the absence of any data, the effect of singing as a therapy for people with bronchiectasis remains unknown.
D I S C U S S I O N
The excluded studies provide the platform for future empirical studies on singing as therapy in the treatment of bronchiectasis. They demonstrated that providing musical approach improved QoL of patients with emphysema, asthma and COPD. However, the evidence of pulmonary function is very weak. An ongoing study identified through searching (Hopkinson 2009) may provide further clinical evidence on the effects of singing on breathlessness. The benefits of certain breathing exercises for people with pulmonary diseases have been documented (Holloway 2004). Singing can be regarded as musical breathing exercises in the clinical context. Additionally, singing can bring enjoyment, which may enhance quality of life and improve adherence with other therapies.
Implications for practice
There is currently insufficient evidence to advocate singing as a therapy in the management of people with bronchiectasis. In the absence of data, we cannot draw any conclusion to support or refute the adoption of singing as an intervention for people with bronchiectasis.
Implications for research
Previous studies have demonstrated that singing has the therapeutic potential to enhance QoL of patients with chronic respiratory disease, such as emphysema, asthma and COPD. Future studies should consider including people with bronchiectasis. Physiology singing, at least certain types of singing, can strengthen respiratory muscles. The design of future RCTs should include detailed information about the type of singing intervention (vocal exercises, song type, pitch and dynamic range) and delivery format (individual or group), length and frequency of sessions, and prescribed singing practice time. Culturally appropriate musical items should be included, taking care that different songs make similar demands on the respiratory and vocal systems. Dose response effects should be assessed.
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A P P E N D I C E S Appendix 1. Term used
